The Prognostic Significance of Fibrosis Detection in Cardiomyopathy

Conditions

Cardiomyopathy, Coronary Artery Disease

Brief summary

The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems and lead to the developement of heart failure Clinical significance Correlation with biomarkers and genetic markers

Detailed description

Patients will undergo cardiovascular magnetic resonance (CMR) to include measurement of left ventricular volumes, ejection fraction, detection of inflammation (via STIR sequences) where appropriate, early gadolinium enhancement, late gadolinium enhancement, first pass perfusion using pharmacological stress imaging (contraindications to include comorbidities that do not permit pharmacological stress agents e.g. severe asthma, severe or symptomatic aortic stenosis)

Vassiliou VS, Pavlou M, Malley T, Halliday BP, Tsampasian V, Raphael CE, Tse G, Vieira MS, Auger D, Everett R, Chin C, Alpendurada F, Pepper J, Pennell DJ, Newby DE, Jabbour A, Dweck MR, Prasad SK.

2021-10-128 citations

10.1038/s41598-021-99788-7

Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction

Brian P. Halliday, Ankur Gulati, Aamir Ali, Kaushik Guha, Simon Newsome et al. (25 authors)

Circulation2017-03-28362 citations

10.1161/circulationaha.116.026910

Prognostic role of CMR in patients presenting with ventricular arrhythmias.

Dawson DK, Hawlisch K, Prescott G, Roussin I, Di Pietro E, Deac M, Wong J, Frenneaux MP, Pennell DJ, Prasad SK.

2013-02-2064 citations

10.1016/j.jcmg.2012.09.012

Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.

O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK.

2010-06-25576 citations

10.1016/j.jacc.2010.05.010

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

No

Inclusion criteria

* presence of an ischaemic or non-ischaemic cardiomyopathic process * no contraindication to contrast enhanced CMR * GFR \>30

Exclusion criteria

* ESRF * Contraindication to CM R

Design outcomes

Primary

Measure	Time frame
All cause mortality	3 years
Ventricular arrhythmias	3 years
Unplanned heart failure admissions	3 years

Secondary

Measure	Time frame
Ejection fraction	3
NYHA status	3

Countries

United Kingdom

Contacts

Primary ContactSanjay K Prasad, MD

s.prasad@rbht.nhs.uk+442073528121

Backup ContactBrian Halliday, MD

b.halliday@rbht.nhs.uk+442073528121

Outcome results